ARTV
Artiva Biotherapeutics, Inc.
Price Chart
Latest Quote
$7.84
+0.42 (+5.66%)
Current Price
| Previous Close | $7.42 |
| Open | $7.42 |
| Day High | $7.97 |
| Day Low | $7.27 |
| Volume | 467,972 |
Stock Information
| Shares Outstanding | 48.59M |
| Total Debt | $10.26M |
| Cash Equivalents | $86.78M |
| Net Income | $-87.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $414.94M |
| EPS (TTM) | $-3.55 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $134.56M |
| Income | $-87.07M |
| Book/sh | $3.55 |
| Cash/sh | $1.79 |
| Employees | 104 |
Financial Ratios
| Quick Ratio | 7.98 |
| Current Ratio | 8.16 |
| Debt/Eq | 11.68 |
Returns & Margins
| ROA | -38.72% |
| ROE | -67.86% |
Ownership
| Insider Ownership | 14.14% |
| Institutional Ownership | 48.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.03 |
| P/B | 2.40 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $35.80 |
Technical Indicators
| SMA20 | $7.80 |
| SMA50 | $9.08 |
| SMA200 | $5.36 |
| RSI | 56.61 |
| ATR | 0.7593 |
| Shares Float | 6.00M |
| Short Float | 3.02% |
| Short Ratio | 1.59 |
| Rel Volume | 2.41 |
Performance History
| Week | +24.67% |
| Month | -18.67% |
| Quarter | +38.19% |
| 6 Months | +178.18% |
| YTD | +101.89% |
| Year | +335.71% |
| 10 Years | -28.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $8.54 | 1,431,700 |
| 2026-06-11 | $8.00 | 1,067,400 |
| 2026-06-10 | $7.42 | 492,400 |
| 2026-06-09 | $7.27 | 997,800 |
| 2026-06-08 | $6.80 | 586,300 |
| 2026-06-05 | $6.85 | 361,000 |
| 2026-06-04 | $7.68 | 312,500 |
| 2026-06-03 | $6.97 | 491,300 |
| 2026-06-02 | $6.87 | 593,700 |
| 2026-06-01 | $7.46 | 289,000 |
| 2026-05-29 | $7.93 | 707,400 |
| 2026-05-28 | $7.61 | 244,900 |
| 2026-05-27 | $7.63 | 309,200 |
| 2026-05-26 | $7.67 | 311,600 |
| 2026-05-22 | $7.87 | 308,900 |
| 2026-05-21 | $7.99 | 425,200 |
| 2026-05-20 | $7.84 | 1,051,800 |
| 2026-05-19 | $8.55 | 844,800 |
| 2026-05-18 | $9.22 | 517,500 |
| 2026-05-15 | $9.78 | 524,500 |
| 2026-05-14 | $10.68 | 389,600 |
| 2026-05-13 | $10.50 | 445,900 |
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
đ° Latest News
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-04-17T18:15:08Z
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
MarketBeat âĸ 2026-04-15T22:02:53Z
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
MarketBeat âĸ 2026-03-04T20:13:25Z
AtaiBeckley names Michael Faerm as finance chief
Proactive âĸ 2026-02-19T13:21:00Z
Undervalued Penny Stocks To Consider In January 2026
Simply Wall St. âĸ 2026-01-26T18:05:29Z
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEOâs Latest Insider Share Sale
Simply Wall St. âĸ 2025-12-19T23:14:54Z
Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders
Simply Wall St. âĸ 2025-12-17T12:04:57Z
Wedbush Predicts Up to ~600% Jump for These 2 âStrong Buyâ Stocks
TipRanks âĸ 2025-12-14T11:05:00Z
3 Promising Penny Stocks With Market Caps Under $200M
Simply Wall St. âĸ 2025-10-29T18:04:50Z
Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101)
Insider Monkey âĸ 2025-10-22T11:41:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $251,000 | $33,492,000 | $4,931,000 |
| Operating Revenue | $0 | $251,000 | $33,492,000 | $4,931,000 |
| Expenses | ||||
| Total Expenses | $89,810,000 | $67,533,000 | $64,163,000 | $64,760,000 |
| Other Income Expense | $-14,000 | $3,754,000 | $512,000 | $200,000 |
| Other Non Operating Income Expenses | $-14,000 | $3,754,000 | $512,000 | $200,000 |
| Net Non Operating Interest Income Expense | $5,959,000 | $5,349,000 | $-2,535,000 | $-1,294,000 |
| Operating Expense | $89,810,000 | $67,533,000 | $64,163,000 | $64,760,000 |
| General And Administrative Expense | $20,270,000 | $17,205,000 | $13,912,000 | $20,776,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Net Interest Income | $5,959,000 | $5,349,000 | $-2,535,000 | $-1,294,000 |
| Interest Income | $5,959,000 | $5,349,000 | $-2,535,000 | $-1,294,000 |
| Normalized Income | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Net Income From Continuing And Discontinued Operation | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Total Operating Income As Reported | $-89,810,000 | $-67,282,000 | $-30,671,000 | $-59,829,000 |
| Net Income Common Stockholders | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Net Income | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Net Income Including Noncontrolling Interests | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Net Income Continuous Operations | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Pretax Income | $-83,865,000 | $-58,179,000 | $-32,694,000 | $-60,923,000 |
| Interest Income Non Operating | $5,959,000 | $5,349,000 | $-2,535,000 | $-1,294,000 |
| Operating Income | $-89,810,000 | $-67,282,000 | $-30,671,000 | $-59,829,000 |
| Per Share | ||||
| Diluted EPS | $-3.43 | $-5.81 | $-1.41 | $-6.51 |
| Basic EPS | $-3.43 | $-5.81 | $-1.41 | $-6.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-87,213,000 | $-64,851,000 | $-28,405,000 | $-58,671,000 |
| Reconciled Depreciation | $2,597,000 | $2,431,000 | $2,266,000 | $1,158,000 |
| EBITDA (Bullshit earnings) | $-87,213,000 | $-64,851,000 | $-28,405,000 | $-58,671,000 |
| EBIT | $-89,810,000 | $-67,282,000 | $-30,671,000 | $-59,829,000 |
| Diluted Average Shares | $24,444,057 | $11,258,851 | $23,281,561 | $9,361,561 |
| Basic Average Shares | $24,444,057 | $11,258,851 | $23,281,561 | $9,361,561 |
| Diluted NI Availto Com Stockholders | $-83,865,000 | $-58,179,000 | $-32,766,000 | $-60,976,000 |
| Research And Development | $69,540,000 | $50,328,000 | $50,251,000 | $43,984,000 |
| Selling General And Administration | $20,270,000 | $17,205,000 | $13,912,000 | $20,776,000 |
| Other Gand A | $20,270,000 | $17,205,000 | $13,912,000 | $20,776,000 |
| Total Unusual Items | - | $3,597,000 | $707,000 | - |
| Total Unusual Items Excluding Goodwill | - | $3,597,000 | $707,000 | - |
| Tax Provision | - | $0 | $72,000 | $53,000 |
| Gain On Sale Of Security | - | $3,597,000 | $707,000 | - |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Total Assets | $130,940,000 | $209,581,000 | $105,114,000 | $133,054,000 |
| Total Non Current Assets | $18,274,000 | $20,950,000 | $25,293,000 | $28,374,000 |
| Other Non Current Assets | $919,000 | $525,000 | $650,000 | $762,000 |
| Current Assets | $112,666,000 | $188,631,000 | $79,821,000 | $104,675,000 |
| Other Current Assets | $4,591,000 | $3,057,000 | $1,092,000 | $1,619,000 |
| Receivables | $67,000 | $146,000 | $1,758,000 | $525,000 |
| Other Receivables | $6,000 | $146,000 | $117,000 | - |
| Cash Cash Equivalents And Short Term Investments | $108,008,000 | $185,428,000 | $76,971,000 | $102,531,000 |
| Cash And Cash Equivalents | $26,701,000 | $40,235,000 | $53,504,000 | $102,531,000 |
| Accounts Receivable | - | $0 | $1,034,000 | $525,000 |
| Non Current Deferred Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $10,942,000 | $14,354,000 | $16,912,000 | $19,448,000 |
| Long Term Debt And Capital Lease Obligation | $7,883,000 | $10,614,000 | $13,316,000 | $15,962,000 |
| Current Debt And Capital Lease Obligation | $3,059,000 | $3,740,000 | $3,596,000 | $3,486,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $20,970,000 | $22,940,000 | $267,129,000 | $273,750,000 |
| Total Non Current Liabilities Net Minority Interest | $7,883,000 | $10,687,000 | $254,902,000 | $248,125,000 |
| Current Liabilities | $13,087,000 | $12,253,000 | $12,227,000 | $25,625,000 |
| Other Current Liabilities | $73,000 | - | - | - |
| Payables And Accrued Expenses | $9,955,000 | $8,513,000 | $8,631,000 | $11,248,000 |
| Payables | $355,000 | $1,121,000 | $614,000 | $1,096,000 |
| Accounts Payable | $355,000 | $1,121,000 | $614,000 | $1,096,000 |
| Other Non Current Liabilities | - | $73,000 | $73,000 | $115,000 |
| Derivative Product Liabilities | - | $0 | $25,100,000 | $0 |
| Non Current Deferred Liabilities | - | - | $0 | $15,635,000 |
| Current Deferred Liabilities | - | - | $0 | $10,891,000 |
| Equity | ||||
| Common Stock Equity | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Total Equity Gross Minority Interest | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Stockholders Equity | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Gains Losses Not Affecting Retained Earnings | $103,000 | $-129,000 | $308,000 | $0 |
| Other Equity Adjustments | $103,000 | $-129,000 | $308,000 | - |
| Retained Earnings | $-330,549,000 | $-246,684,000 | $-181,311,000 | $-152,591,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $216,413,000 | $216,413,000 |
| Other | ||||
| Ordinary Shares Number | $24,595,550 | $24,291,607 | $23,281,561 | $23,281,561 |
| Share Issued | $24,595,550 | $24,291,607 | $23,281,561 | $23,281,561 |
| Tangible Book Value | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Invested Capital | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Working Capital | $99,579,000 | $176,378,000 | $67,594,000 | $79,050,000 |
| Capital Lease Obligations | $10,942,000 | $14,354,000 | $16,912,000 | $19,448,000 |
| Total Capitalization | $109,970,000 | $186,641,000 | $-162,015,000 | $-140,696,000 |
| Additional Paid In Capital | $440,413,000 | $433,451,000 | $18,988,000 | $11,895,000 |
| Capital Stock | $3,000 | $3,000 | $0 | $0 |
| Common Stock | $3,000 | $3,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $7,883,000 | $10,614,000 | $13,316,000 | $15,962,000 |
| Current Capital Lease Obligation | $3,059,000 | $3,740,000 | $3,596,000 | $3,486,000 |
| Current Accrued Expenses | $9,600,000 | $7,392,000 | $8,017,000 | $10,152,000 |
| Net PPE | $17,355,000 | $20,425,000 | $24,643,000 | $27,612,000 |
| Accumulated Depreciation | $-8,457,000 | $-5,923,000 | $-3,532,000 | $-1,265,000 |
| Gross PPE | $25,812,000 | $26,348,000 | $28,175,000 | $28,877,000 |
| Leases | $867,000 | $410,000 | $390,000 | $283,000 |
| Other Properties | $23,237,000 | $24,450,000 | $26,307,000 | $27,127,000 |
| Machinery Furniture Equipment | $1,708,000 | $1,488,000 | $1,478,000 | $1,467,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $61,000 | $0 | $607,000 | $0 |
| Other Short Term Investments | $81,307,000 | $145,193,000 | $23,467,000 | $0 |
| Non Current Deferred Revenue | - | - | $0 | $15,635,000 |
| Current Deferred Revenue | - | - | $0 | $10,891,000 |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-79,338,000 | $-55,674,000 | $-50,688,000 | $-57,128,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-76,751,000 | $-55,032,000 | $-47,430,000 | $-50,829,000 |
| Cash Flow From Continuing Operating Activities | $-76,751,000 | $-55,032,000 | $-47,430,000 | $-50,829,000 |
| Operating Gains Losses | - | $3,597,000 | $707,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-2,587,000 | $-642,000 | $-3,258,000 | $-6,299,000 |
| Investing Cash Flow | $63,411,000 | $-120,463,000 | $-25,975,000 | $-6,299,000 |
| Cash Flow From Continuing Investing Activities | $63,411,000 | $-120,463,000 | $-25,975,000 | $-6,299,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-4,183,000 | $-12,000 | $-5,000 |
| Issuance Of Capital Stock | $0 | $166,507,000 | $0 | - |
| Financing Cash Flow | $9,000 | $162,226,000 | $24,391,000 | $-1,264,000 |
| Cash Flow From Continuing Financing Activities | $9,000 | $162,226,000 | $24,391,000 | $-1,264,000 |
| Net Other Financing Charges | $-230,000 | - | $24,393,000 | $-1,591,000 |
| Net Common Stock Issuance | $0 | $162,324,000 | $-12,000 | $-5,000 |
| Common Stock Issuance | $0 | $166,507,000 | $0 | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-132,000 | $-149,000 | $0 | - |
| End Cash Position | $27,162,000 | $40,493,000 | $53,762,000 | $102,776,000 |
| Beginning Cash Position | $40,493,000 | $53,762,000 | $102,776,000 | $161,168,000 |
| Changes In Cash | $-13,331,000 | $-13,269,000 | $-49,014,000 | $-58,392,000 |
| Proceeds From Stock Option Exercised | $371,000 | $51,000 | $10,000 | $332,000 |
| Common Stock Payments | $0 | $-4,183,000 | $-12,000 | $-5,000 |
| Net Issuance Payments Of Debt | $-132,000 | $-149,000 | $0 | - |
| Net Long Term Debt Issuance | $-132,000 | $-149,000 | $0 | - |
| Long Term Debt Payments | $-132,000 | $-149,000 | $0 | - |
| Net Investment Purchase And Sale | $65,998,000 | $-119,821,000 | $-22,717,000 | $0 |
| Sale Of Investment | $110,873,000 | $56,350,000 | $26,800,000 | $0 |
| Purchase Of Investment | $-44,875,000 | $-176,171,000 | $-49,517,000 | $0 |
| Net PPE Purchase And Sale | $-2,587,000 | $-642,000 | $-3,258,000 | $-6,299,000 |
| Purchase Of PPE | $-2,587,000 | $-642,000 | $-3,258,000 | $-6,299,000 |
| Change In Working Capital | $-424,000 | $-325,000 | $-28,280,000 | $-3,866,000 |
| Change In Other Working Capital | $-21,000 | $43,000 | $-26,381,000 | $-2,383,000 |
| Change In Other Current Assets | $-191,000 | $125,000 | $139,000 | $-121,000 |
| Change In Payables And Accrued Expense | $1,243,000 | $-140,000 | $-1,320,000 | $-615,000 |
| Change In Accrued Expense | $2,003,000 | $-659,000 | $-912,000 | $-805,000 |
| Change In Payable | $-760,000 | $519,000 | $-408,000 | $190,000 |
| Change In Account Payable | $-760,000 | $519,000 | $-408,000 | $190,000 |
| Change In Prepaid Assets | $-1,534,000 | $-1,965,000 | $516,000 | $-764,000 |
| Change In Receivables | $79,000 | $1,612,000 | $-1,234,000 | $-57,000 |
| Changes In Account Receivables | $0 | $1,034,000 | $-510,000 | $-57,000 |
| Stock Based Compensation | $6,821,000 | $6,980,000 | $7,053,000 | $6,584,000 |
| Amortization Of Securities | $-1,880,000 | $-2,342,000 | $-456,000 | $0 |
| Depreciation Amortization Depletion | $2,597,000 | $2,431,000 | $2,266,000 | $1,158,000 |
| Depreciation And Amortization | $2,597,000 | $2,431,000 | $2,266,000 | $1,158,000 |
| Net Income From Continuing Operations | $-83,865,000 | $-65,373,000 | $-28,720,000 | $-58,788,000 |
| Income Tax Paid Supplemental Data | - | $0 | $83,000 | $0 |
| Gain Loss On Investment Securities | - | $3,597,000 | $707,000 | - |
| Change In Other Current Liabilities | - | - | $0 | $74,000 |
| Asset Impairment Charge | - | - | $0 | $4,083,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-11